Conclusion
The role of NAFLD in the pathophysiology of CV abnormalities and hence its independent contribution to an increased risk of CV morbidity and mortality is increasingly evidenced by studies in animal models and by clinical data. Whether NAFL is still to be considered benign in this regard and whether the risk is hence confined to NASH is currently unclear but the risk seems at least to be more pronounced in NASH patients compared with NAFL. As the role of NAFLD in CVD becomes clearer, this aspect of NAFLD should probably be incorporated in the future guidelines on its treatment indications and paradigms.